Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion, and Therapeutic Resistance

Generation of profound anti-tumor immunity by AUR109, a spectrum-selective kinase inhibitor, either as a single agent or in combination with immune checkpoint inhibitors

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.